Calumet, Inc. (CLMT)
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-15
$57.55+1.77%
Close 2026-09-15 · 1-day change
NASDAQMaterialsChemicals - SpecialtySnapshot 2026-09-15
Research Workspace
Put CLMT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Specialty Chemicals is in recovery. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 42%, softest on share dilution.
View QualityManagement screens weak on capital allocation, earnings delivery.
View ManagementExpectations look high — the market is pricing in about 27% growth a year, above the roughly 2% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 15% in its worst 12-month stretch.
View RiskCLMT's growth depends on expanding sustainable aviation fuel (SAF) production capacity. Revenue grew 40% year over year, but the latest quarter missed expectations. It trades at 1.1× price-to-sales, below the peer median of 1.4×. The market is pricing in more growth than forecast, indicating expectations look full. A specific risk is a potential guidance cut, which could lead to a significant negative reaction. Peer multiples imply a price about 25% below where it trades (it looks expensive on this basis). Our read is provisional.
Trailing returns as of 2026-09-15. CLMT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 6 analysts currently covering CLMT (as of Sep 2026).
Based on 3 Wall Street analysts offering 12-month price targets for CLMT in the last 4 months.
Continue this research
Compare CLMT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CLMT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 4 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Specialty Chemicals — fair value, gap to price, and forward P/E.
Compare the value case
Put CLMT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Accelerate deleveraging through debt reduction
S&P upgrade supports debt reduction efforts.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $57.55
The last 12 months of price, then the range of analyst 12-month targets from today’s $57.55.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
